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An initial tranche of results from day-to-day use of a robotic system for setting
up 100 nl-scale vapour-diffusion sitting-drop protein crystallizations has been
surveyed. The database of over 50 unrelated samples represents a snapshot of
projects currently at the stage of crystallization trials in Oxford research groups
and as such encompasses a broad range of proteins. The results indicate that the
nanolitre-scale methodology consistently identi®es more crystallization condi-
tions than traditional hand-pipetting-style methods; however, in a number of
cases successful scale-up is then problematic. Crystals grown in the initial 100 nl-
scale drops have in the majority of cases allowed useful characterization of X-
ray diffraction, either in-house or at synchrotron beamlines. For a signi®cant
number of projects, full X-ray diffraction data sets have been collected to 3 AÊ
resolution or better (either in-house or at the synchrotron) from crystals grown
at the 100 nl scale. To date, ®ve structures have been determined by molecular
replacement directly from such data and a further three from scale-up of
conditions established at the nanolitre scale.
1. Introduction
The application of nanolitre liquid dispensing technologies to
protein crystallization trials offers the opportunity to reduce
by one or more orders of magnitude the amount of protein
required for initial screening experiments (Santarsiero et al.,
2002). Much of the impetus for the implementation of such
technology has been generated by its utility for high-
throughput structural genomic pipelines. However, the
signi®cant reduction in sample quantity coupled to a conve-
nient and reproducible methodology is highly relevant to
classical protein crystallographic research projects.
In the accompanying paper (Walter et al., 2003) the modi-
®cation of commercially available equipment and the design
of a protocol for high-throughput nanolitre-scale crystal-
lization experiments is reported. This methodology has
already been applied to a broad range of proteins drawn from
on-going local crystallographic research projects. The experi-
ences culled from the ®rst few months of operation on an
essentially random set of over 50 target proteins and some
1200 crystallization plates guided the development of the
protocols reported in the accompanying paper (Walter et al.,
2003). They provide encouraging evidence of the general
applicability and advantages of automation and miniaturiza-
tion for crystallization screening and, indeed, the growth of
data-collection-quality crystals.
2. Materials and methods
2.1. Range of protein samples
The survey is based on results from 51 proteins. No selec-
tion criteria were applied to the sample proteins other than
that they were produced for crystallization trials by the
authors as part of bona ®de structural projects in local
research groups. As a result, the protein types span various
classes of bacterial, fungal and mammalian enzymes, intra-
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cellular and extracellular proteins including the extracellular
regions of cell surface receptors, structural and non-structural
viral proteins. Samples have been variously produced in E.
coli, insect and mammalian expression systems, generally as
soluble proteins, but several examples of refolded proteins are
also included. Molecular weights range from 7 to 300 kDa with
several samples comprising protein±protein or protein±small-
molecule (inhibitor/substrate/cofactor) complexes. The ratio
of freshly puri®ed to frozen samples was approximately 3:2,
with most having purities in the 95±100% range. Statistics do
not allow a useful quantitative correlation of crystallization
results with sub-categories of sample type or quality.
2.2. Crystallization-screen reagents
The vast majority of the samples were subjected to a stan-
dard survey comprising 5  96 crystallization conditions
assembled from commercially available kits: Crystal Screen,
Crystal Screen 2, PEG/Ion Screen, Grid Screen PEG 6000,
Grid Screen Ammonium Sulfate, Natrix, Crystal Screen Cryo,
Grid Screen PEG/LiCl, Grid Screen Sodium Chloride, Grid
Screen MPD and Quik Screen from Hampton Research (CA,
USA), and Emerald BioStructures Wizard Screens I and II
from deCODE Genetics (WA, USA).
2.3. Crystallization-screen methodologies
Crystallization trials were conducted by the individual users
following training on use of the robotic equipment and advice
on the current protocols. Although the majority of the samples
were treated identically over the period surveyed, some
re®nement of protocols did occur in response to the experi-
ence gained, most notably a switch from pipetting the reser-
voir drop ®rst to pipetting the protein drop ®rst. Typically,
protein samples were at 5±15 mg mlÿ1 (somewhat lower
concentrations were used for some of the largest molecular
weight samples and substantially higher concentrations for a
few of the very low molecular weight proteins). Set up of the
96-well crystallization trials was always carried out at room
temperature (293±295 K); however, some users then trans-
ferred their trials to incubate at 278 or 288 K.
A detailed description of the equipment and protocol
design is given in the accompanying paper (Walter et al., 2003).
Brie¯y, sitting-drop vapour-diffusion experiments were set up
in ¯at-bottom-platform 96-well crystallization plates (Greiner,
Bio-One Ltd, Stonehouse, UK). 96 reservoir solutions (each of
95 ml) were pipetted simultaneously from pre-formatted 96-
well master blocks using a Robbins Hydra-96 microdispenser
(Apogent Discoveries, Wilmslow, UK). 100 nl:100 nl drops of
protein solution and reservoir solution were dispensed (one
plate at a time) using a Cartesian Technologies Microsys
MIC4000 (Genomic Solutions, Huntingdon, UK), with adap-
tations as detailed in the accompanying paper by Walter et al.
(2003). Typically, protein drops were set up ®rst using a single
tip in line-dispense mode. Reservoir drops were then added
using all eight tips in single-dispense mode. Crystallization
plates were sealed with transparent self-adhesive plastic foils
as supplied by Greiner (Viewseal) and inspected manually
using standard optical microscopes. Crystals were prepared for
characterization and X-ray data collection using well estab-
lished cryo-crystallographic methods. In-house X-rays gener-
ated using an RU-300 rotating-anode generator (Rigaku;
operating at 48 kV, 100 mA and ®tted with Osmic blue
multilayer optics) were detected using MarResearch imaging-
plate detectors. Synchrotron radiation was accessed on
beamlines at either the UK Synchrotron Radiation Source
(SRS; Daresbury) or the European Synchrotron Radiation
Facility (ESRF; Grenoble, France).
3. Results and discussion
3.1. Success rate, crystal quality and utility
Statistics on the outcome of nanolitre-scale crystallization
screens for 51 protein samples are presented in Fig. 1. Of the
51, 18 yielded no crystals in the nanolitre-scale screens (some
`objects' were tested in-house for diffraction but it remains
inconclusive whether these were crystalline). None of these 18
samples was reported to have crystallized using standard
hand-pipetting methods. Of the 33 samples which yielded
identi®able crystals in the nanolitre-scale screen, 23 were
considered to be of suf®cient size to be tested directly for
diffraction. Scale-up of conditions from the nanolitre-scale to
standard (hand-pipetted) crystallization drops proved
problematic for a signi®cant number of samples (see below)
but of the ten projects for which nanolitre-scale crystals were
considered too small to test for diffraction, three scaled up
successfully, providing crystals suitable for full X-ray data
collection.
Of the 23 projects with samples for which nanolitre-scale
crystals were tested directly, the majority have been able to
make signi®cant progress (four projects report currently
insurmountable problems with scale-up and/or optimization of
crystal growth). Full X-ray diffraction data set collection from
nanolitre-scale crystals has been considered to be practical/
useful for three projects in-house and ®ve projects at the
synchrotron. Of the three collected in-house, all diffracted to
maximum Bragg spacings of 3 AÊ or better. In one case, a
Figure 1
Summary of direct results from nanolitre crystallization trials. No results
from subsequent scaling-up are included. The numbers of proteins
making up each segment are shown.
crystal grown from a 100 nl drop of 14 mg mlÿ1 protein solu-
tion plus 100 nl reservoir yielded an in-house data set to 2.5 AÊ
resolution (further details are given in Fig. 2 and data-scaling
statistics are given in Table 1).
Although the number of samples investigated to date is too
small to justify a statistical analysis of the results, of the
proteins for which potentially useful X-ray diffraction data
have been collected, about 30% were produced in eukaryotic
expression systems and about 70% were proteins of eukar-
yotic or viral origin. The diffraction-quality crystals include
protein±oligonucleotide and protein±inhibitor complexes and
most are multi-domain. Overall, we see no indication that the
use of small drops introduces any bias into the outcome of the
experiments.
3.2. Nanolitre scale versus standard drop-size screens
Not all of the 51 sample proteins have been screened for
crystallization conditions using standard hand-pipetting tech-
niques (the nanolitre technology has become the method of
choice for many of the authors), but where comparisons can
been drawn, no protein fails to crystallize in the nanolitre-
scale drops which has succeeded in the standard drops
(although for one project fewer conditions yielded crystals at
the nanolitre scale). For a signi®cant number of samples, the
nanolitre scale screen identi®ed new crystallization conditions
and for at least ®ve of the proteins, crystals could only been
grown by this method, a ®nding echoing the report of
Bodenstaff et al. (2002). At present, problems are frequently
encountered in scale-up and crystal optimization. One factor
that may contribute to this is the generation, due to mixing in
the Cartesian tips, of a `protein gradient' across the plate, as
described in the accompanying paper (Walter et al., 2003).
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Figure 2
(a) Crystal grown from a 100 nl drop of domain 11 of the insulin-like
growth factor 2 receptor (IGF2R-Dom11; Brown et al., 2002) plus 100 nl
reservoir solution as part of a screen for complexes with a putative small-
molecule inhibitor. This is an example of a crystal form discovered in
nanolitre-scale trials which had not previously been seen in microlitre-
scale trials. (b) Representative in-house diffraction image from the crystal
shown in (a). Data-scaling statistics are given in Table 1.
Table 1
Data-scaling statistics for the IGF2R-Dom11 crystal (see Fig. 2).
Values in parentheses correspond to the highest resolution shell (2.59±2.50 AÊ ).
Space group P3121
Resolution range (AÊ ) 20±2.5
Wavelength (AÊ ) 1.54
Measurements 18 482
Unique re¯ections 4883
Completeness (%) 95.7 (99.8)
I/(I) 13.9 (5.0)
Rmerge =
P jI ÿ hIij=PhIi (%) 11.7 (36.1)
Figure 3
Time-lapse photographs showing the formation of glucose isomerase
crystals. Images (a) and (b) show crystals grown in 30% polyethylene
glycol 400, 0.1 M Na-HEPES, pH 7.5, 0.2 M magnesium chloride
(Hampton research Crystal Screen solution #23), and photographed at t
= 0 h and t = 40 h, respectively. Images (c) and (d) show crystals grown in
30% 2-propanol, 0.1 M Tris-HCl, pH 8.5, 0.2 M ammonium acetate
(Hampton research Crystal Screen solution #19), and again photo-
graphed at t = 0 h and t = 40 h, respectively. Images were taken by the
OASIS 1700 image-acquisition system (Veeco, Cambridge, UK).
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Until this problem is solved, it may be necessary to take this
into consideration during optimization and scale-up. In our
experience, re®nement of crystallization conditions initially
identi®ed using nanolitre-scale technology is generally best
done by re-screening with the Cartesian robot and a custo-
mized screen.
3.3. Rate of crystal nucleation and growth
Crystal growth times in nanolitre-scale drops still show
substantial variation from sample to sample (example time-
lapse images are shown in Fig. 3). One author reports that
crystals are ®rst visible within 10 min of crystallization-screen
set up, growing to maximum size over 2±5 days. Others report
crystals appearing between 12 h and 3 weeks of screen set up.
Kuhn et al. (2002) have reported a trend towards more rapid
crystal growth in nanolitre-scale trials and, although similar
behaviour has been noted in this survey, the experiences
reported for several of the current samples indicates that this
is by no means generic. Several samples do, however, reveal
increased problems with multiple nucleation sites in micro-
litre-scale drops compared with nanolitre-scale drops, a
feature which has proved problematic for scale-up attempts.
3.4. Technical glitches
Day-to-day use of the nanolitre technology uncovered
several technical glitches. The ®rst encountered was a frequent
tendency for drops to migrate to the edges of the ¯at wells,
making visualization and imaging dif®cult. This movement was
most frequent when reservoir drops were pipetted ®rst and
was rarely seen when protein was dispensed ®rst. There was no
direct correlation between reservoir constituents and drop
migration, and there was no evidence of a static charge on the
plate being responsible. As a consequence of migration, there
were occasions when protein and reservoir drops failed to mix,
giving separate drops in the well. As a result of these obser-
vations, the experimental procedure was altered so that
protein is dispensed before reservoir; now drop migration
rarely occurs and if it does, the drops have already mixed.
Some users reported drop evaporation despite the presence
of the Viewseal foil on the plate. As noted in the accom-
panying paper (Walter et al., 2003), these foils contain an
encapsulated sealant, which is released only where the foil is
pressed against a solid support. Since evaporation problems
were not widespread, they probably re¯ected poor sealing; it
should be noted that pressing using a ®rm surface such as a
®ngernail produces a much better seal than simply pressing
with ones thumb.
As part of the experimental procedure, there are several
wash steps where the ceramic tips are cleaned and dried under
a vacuum. Despite this, tips can eventually become blocked,
presumably because of an internal build up of salts and other
components of the reservoir solutions. Blockages can be
precluded by regularly detaching and immersing the tips in a
mild detergent solution and cleaning in an ultrasonic water
bath for 5 min.
4. Conclusions
We have demonstrated that the protocol described is capable
of producing useful crystals at a high success rate. Further
developments will include a protocol for the systematic use of
additive screens and automated optimization of initial condi-
tions. In addition, we would like to explore the use of both
smaller (for screening) and larger (for optimization) drops.
Reduction of the protein and reservoir solution volumes
required for screening crystallization conditions, coupled with
increases in accuracy, ef®ciency and reproducibility, constitute
the obvious bene®ts of an automated high-throughput
procedure. The observation that nanolitre-scale procedures
can lead directly to the growth of diffraction-quality crystals
yielding full data sets is an enormous bonus. We have found
that the automation described in this paper can be applied in
classical protein crystallography laboratories and it is easy to
envisage similar procedures replacing traditional hand-pipet-
ting methods for crystallization screening and optimization.
Indeed, the method has been embraced enthusiastically by the
crystallographic community in Oxford, such that it is already
becoming the preferred modus operandi for many workers.
Although there is a signi®cant capital cost with respect to the
equipment, experience to date indicates that for an active
laboratory, especially one routinely producing proteins in
eukaryotic expression systems, this cost is likely to be
recouped relatively quickly. Furthermore, where the level of
protein production is very low or cofactors or ligands are very
expensive, small drops may allow crystallization experiments
to be contemplated which would otherwise be prohibitively
expensive.
The Oxford Protein Production Facility is a Medical
Research Council (MRC) funded pilot project for the UK and
is part of the Structural Proteomics IN Europe (SPINE)
consortium (European Commission Grant No. QLG2-CT-
2002-00988). Protein samples were drawn from on-going
research projects funded by the Biotechnology and Biological
Science Research Council, Cancer Research UK, the
European Commission, The Human Frontier Science
Program, MRC, The Wellcome Trust and Arrow Therapeutics.
We thank the staff at SRS Daresbury, ESRF Grenoble and
MRC France for assistance with data collection.
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